Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Female brain forms fear memories through unique molecular process

Women are twice as likely as men to develop post-traumatic stress disorder (PTSD) - and new research may offer a biological clue as to why.

8 Jun 2026

Researchers develop compound 10 to slow Alzheimer's disease progression

Researchers from ETH Zurich have developed an active ingredient that slows down the progression of typical Alzheimer’s symptoms in mice. This new substance protects nerve cells and could in future alleviate the suffering of Alzheimer’s patients. The active ingredient also shows anti-aging effects.

8 Jun 2026

Grant fuels research into SYNGAP1-linked behavioral abnormalities

CURE SYNGAP1 501(c)(3) is pleased to announce a $130,000 grant to Dr. Helen Willsey and Dr. David Kastner at the University of California, San Francisco (UCSF).

5 Jun 2026

New artificial intelligence tool helps clinicians distinguish between dementia types

Alzheimer's disease and related dementias are expected to more than double by 2060. As June marks Alzheimer's and Brain Awareness Month, three University of Florida researchers are working to improve clinicians' ability to distinguish between these diseases - a critical step toward earlier diagnosis and better outcomes.

5 Jun 2026

Antibody fragment offers safer alternative for Alzheimer disease treatment

In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).

5 Jun 2026

Senior Care Authority kicks off Alzheimer's and Brain Awareness Month with six science-backed habits that may help reduce dementia risk

An estimated 7.4 million Americans aged 65 and older are now living with Alzheimer's disease, according to the Alzheimer's Association's 2026 Alzheimer's Disease Facts and Figures report, and that number is projected to climb to nearly 13 million by 2050.

5 Jun 2026

Microglia transitions act as critical turning point in Alzheimer's

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer's disease pathology leads to dementia.

4 Jun 2026

Higher genetic pulse pressure risk associated with dementia-related mortality

When looking at genetic variants in a person's DNA that predispose them to disease, a new study has found having a higher number of genetic variants for increased pulse pressure is associated with a small, increased risk of dementia as a contributing cause of death.

3 Jun 2026

Long-term exposure to air pollution associated with lower semantic memory

A new study by researchers at UC Davis Health and Kaiser Permanente found that higher exposure to very small air pollution particles (PM2.5) over a 17-year span was associated with lower semantic memory.

3 Jun 2026

Study discovers memory switchboard that protects past knowledge

The brain may reuse some cells to store many different memories without mixing them up with or erasing older memories, a new study in mice suggests.

3 Jun 2026

Acupuncture improves muscle function recovery in stroke patients

Paralysis on one side of the body is common after stroke. A new study in CNS Neuroscience & Therapeutics demonstrates that acupuncture can significantly improve muscle function recovery in patients who experienced a stroke, with this recovery correlating to increases in grey matter volume in certain regions of the brain related to cognitive-motor integration.

3 Jun 2026

New reference models track lifespan changes in brain wiring

Researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC have created one of the largest reference models ever developed for the human brain, using diffusion MRI scans from more than 54,000 people to chart how the brain's communication pathways develop, mature, and decline across the lifespan.

2 Jun 2026

Cellular reprogramming helps outsmart progressive Alzheimers disease

A team led by researcher José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH), together with researcher Johannes Gräff at the École Polytechnique Fédérale de Lausanne (EPFL), has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their protective function against Alzheimer's disease.

2 Jun 2026

New brain probe simultaneously records and controls neuron activity

A new breakthrough technology, co-developed by UCL scientists, that simultaneously records and manipulates neuron activity deep within the brain could transform our understanding of neural circuits and neurological conditions, such as Alzheimer's disease and schizophrenia.

1 Jun 2026

Lower Alzheimer’s amyloid levels in Black and Latinx adults

Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.

1 Jun 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Researchers uncover new clues about the origin of Alzheimer's tau tangles

Researchers at Columbia University have uncovered new clues about the earliest molecular events that may trigger Alzheimer's disease, shedding light on how toxic tau filaments begin to form in the brain.

29 May 2026

Gladstone scientists track exact routes used to clear brain waste

Think of the brain as if it were a house. Insulated from its environment, a house relies on complex networks-pipes, drains, and disposal systems-that interface with the outside world to keep the home functional on the inside.

29 May 2026

Advanced tau imaging improves early Alzheimer’s disease detection accuracy

A new brain imaging test can detect a key hallmark of Alzheimer's disease before symptoms appear and earlier than the method currently used in clinical practice in the United States and Europe, report University of Pittsburgh School of Medicine researchers today in The Lancet.

28 May 2026

Blood biomarkers may detect Alzheimer’s risk before symptoms appear

For the first time, researchers found blood biomarkers for Alzheimer's disease that correlated with minor cognitive differences in midlife adults who did not have dementia.

28 May 2026